Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Steroid receptor RNA activator protein (SRAP) expression as a prognostic factor in ER+ human breast tumors.

Yan Y, Penner CC, Skliris GP, Cooper C, Nugent Z, Blanchard A, Hamedani MK, Wang X, Myal Y, Murphy LC, Leygue E.

J Cancer Res Clin Oncol. 2013 Oct;139(10):1637-47. doi: 10.1007/s00432-013-1485-2. Epub 2013 Aug 2.

PMID:
23907597
2.

CARM1 is an important determinant of ERα-dependent breast cancer cell differentiation and proliferation in breast cancer cells.

Al-Dhaheri M, Wu J, Skliris GP, Li J, Higashimato K, Wang Y, White KP, Lambert P, Zhu Y, Murphy L, Xu W.

Cancer Res. 2011 Mar 15;71(6):2118-28. doi: 10.1158/0008-5472.CAN-10-2426. Epub 2011 Jan 31.

3.

A phosphorylation code for oestrogen receptor-alpha predicts clinical outcome to endocrine therapy in breast cancer.

Skliris GP, Nugent ZJ, Rowan BG, Penner CR, Watson PH, Murphy LC.

Endocr Relat Cancer. 2010 Jun 3;17(3):589-97. doi: 10.1677/ERC-10-0030. Print 2010 Sep.

4.

Estrogen receptor alpha phosphorylated at tyrosine 537 is associated with poor clinical outcome in breast cancer patients treated with tamoxifen.

Skliris GP, Nugent Z, Watson PH, Murphy LC.

Horm Cancer. 2010 Aug;1(4):215-21. doi: 10.1007/s12672-010-0049-z.

PMID:
21761367
5.

Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/younger breast cancer patients.

Yan Y, Skliris GP, Penner C, Chooniedass-Kothari S, Cooper C, Nugent Z, Blanchard A, Watson PH, Myal Y, Murphy LC, Leygue E.

Breast Cancer Res. 2009;11(5):R67. doi: 10.1186/bcr2359.

6.

The relevance of phosphorylated forms of estrogen receptor in human breast cancer in vivo.

Murphy LC, Skliris GP, Rowan BG, Al-Dhaheri M, Williams C, Penner C, Troup S, Begic S, Parisien M, Watson PH.

J Steroid Biochem Mol Biol. 2009 Mar;114(1-2):90-5. doi: 10.1016/j.jsbmb.2009.01.017. Epub 2009 Feb 6. Review.

PMID:
19429437
7.

Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype.

Blanchard AA, Skliris GP, Watson PH, Murphy LC, Penner C, Tomes L, Young TL, Leygue E, Myal Y.

Virchows Arch. 2009 Jun;454(6):647-56. doi: 10.1007/s00428-009-0770-6. Epub 2009 Apr 23.

PMID:
19387682
8.

Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor alpha (ERalpha) in tissue microarrays of ERalpha positive human breast carcinomas.

Skliris GP, Rowan BG, Al-Dhaheri M, Williams C, Troup S, Begic S, Parisien M, Watson PH, Murphy LC.

Breast Cancer Res Treat. 2009 Dec;118(3):443-53. doi: 10.1007/s10549-008-0267-z. Epub 2008 Dec 23.

9.

Expression of small breast epithelial mucin (SBEM) protein in tissue microarrays (TMAs) of primary invasive breast cancers.

Skliris GP, Hubé F, Gheorghiu I, Mutawe MM, Penner C, Watson PH, Murphy LC, Leygue E, Myal Y.

Histopathology. 2008 Feb;52(3):355-69. doi: 10.1111/j.1365-2559.2007.02955.x.

10.

Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target.

Skliris GP, Leygue E, Watson PH, Murphy LC.

J Steroid Biochem Mol Biol. 2008 Mar;109(1-2):1-10. doi: 10.1016/j.jsbmb.2007.12.010. Epub 2007 Dec 8. Review.

PMID:
18243688
11.

Targeting the EGFR pathway for cancer therapy.

Johnston JB, Navaratnam S, Pitz MW, Maniate JM, Wiechec E, Baust H, Gingerich J, Skliris GP, Murphy LC, Los M.

Curr Med Chem. 2006;13(29):3483-92. Review.

PMID:
17168718
12.

Potential role of estrogen receptor alpha (ERalpha) phosphorylated at Serine118 in human breast cancer in vivo.

Murphy LC, Weitsman GE, Skliris GP, Teh EM, Li L, Peng B, Davie JR, Ung K, Niu YL, Troup S, Tomes L, Watson PH.

J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):139-46. Epub 2006 Nov 7. Review.

PMID:
17092701
13.

Estrogen receptor-alpha phosphorylated at Ser118 is present at the promoters of estrogen-regulated genes and is not altered due to HER-2 overexpression.

Weitsman GE, Li L, Skliris GP, Davie JR, Ung K, Niu Y, Curtis-Snell L, Tomes L, Watson PH, Murphy LC.

Cancer Res. 2006 Oct 15;66(20):10162-70.

14.

Estrogen receptor-beta regulates psoriasin (S100A7) in human breast cancer.

Skliris GP, Lewis A, Emberley E, Peng B, Weebadda WK, Kemp A, Davie JR, Shiu RP, Watson PH, Murphy LC.

Breast Cancer Res Treat. 2007 Jul;104(1):75-85. Epub 2006 Sep 29.

PMID:
17009105
15.

Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours.

Skliris GP, Leygue E, Curtis-Snell L, Watson PH, Murphy LC.

Br J Cancer. 2006 Sep 4;95(5):616-26. Epub 2006 Aug 1.

16.

Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model.

Skliris GP, Munot K, Bell SM, Carder PJ, Lane S, Horgan K, Lansdown MR, Parkes AT, Hanby AM, Markham AF, Speirs V.

J Pathol. 2003 Oct;201(2):213-20.

PMID:
14517838
17.

Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue.

Skliris GP, Parkes AT, Limer JL, Burdall SE, Carder PJ, Speirs V.

J Pathol. 2002 Jun;197(2):155-62.

PMID:
12015738
18.

Distinct expression patterns of ER alpha and ER beta in normal human mammary gland.

Speirs V, Skliris GP, Burdall SE, Carder PJ.

J Clin Pathol. 2002 May;55(5):371-4.

19.

Phylogenetic and antigenic characterization of new fish nodavirus isolates from Europe and Asia.

Skliris GP, Krondiris JV, Sideris DC, Shinn AP, Starkey WG, Richards RH.

Virus Res. 2001 May;75(1):59-67.

PMID:
11311428
20.

Immunohistochemical detection of ERbeta in breast cancer: towards more detailed receptor profiling?

Skliris GP, Carder PJ, Lansdown MR, Speirs V.

Br J Cancer. 2001 Apr 20;84(8):1095-8.

21.

Supplemental Content

Loading ...
Support Center